AS/Spondyloarthritis
The big news this week: the approval of deucravacitinib (a new class of drug?) for psoriasis; the 2022 ACR guidance on glucocorticoid-induced osteoporosis; a national poll of older adults over the age of 50 who claimed self-reported or doctor-diagnosed arthritis; and much more. Let's review these and other news, journal reports and announcements from this past week.
Dr. John Cush RheumNow
2 years 9 months ago
Open label, noninferiority study TNFi withdrawal in 64 PsA & 58 axSpA pts. 2/3 tapered by dz activity T2T strategy (N=81) & 1/3 continued TNFi. At 12 mos. LDA seen in 69% w/ Tapering (~avg 53% dose) vs 73% no-tapering group (91% dose) https://t.co/K6WFaesyRt https://t.co/zqo6nVGtqW
Dr. John Cush RheumNow
2 years 9 months ago
534 PsA & 470 AS pts (SERENA study) on Secukinumab for avg of ~88wks - 5.8% PsA & 8.9% AS pts had sudden stop of SEC (for avg ~25wks) (reasons? Mostly AE 58% or pt decision 10%). While TJC & SJC increased, dz control returned w/ restarting SEC https://t.co/GFxj3b06Ra https://t.co/B2ubakq8Ql
Dr. John Cush RheumNow
2 years 9 months ago
The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/ZqMAc8jV3U https://t.co/3iCGnzsPI5
Charlie Clements ClementsCharl96
2 years 9 months ago
Nice table from the Poddubny et al., (2021) study which looks at some of the different characteristics between Axial SpA vs Axial PsA.
Axial PsA tends to have;
- Less frequent IBP
- Less HLAB27 +‘ve
- More frequent C-spine involvement https://t.co/XXQKBSfSQq
Dr. John Cush RheumNow
2 years 9 months ago
The ACR is developing a new clinical practice guideline for systemic autoimmune rheumatic disease with interstitial lung disease (ILD). The Call for Public Comment is open until September 29, 2022. https://t.co/UxXDbGEQlh https://t.co/zGoBpbKLTC
Dr. John Cush RheumNow
2 years 9 months ago
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/xchK5ETmg3 https://t.co/F9klsUE5er
Dr. John Cush RheumNow
2 years 9 months ago
How to predict IBD in AS/SpA? Study of 82 SpA pts undergoing colonoscopy showed: Rectal bleeding, diarrhea, abdominal pain, high Dz activity and calprotectin levels were suggestive of abnormal ileum inflammation and risk of IBD https://t.co/10PKp7uwmx https://t.co/tnU5tu6Ffp
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.
Dr. John Cush RheumNow
2 years 9 months ago
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/b9Qa6fL9eM https://t.co/6nRu0iuP1a
Dr. John Cush RheumNow
2 years 9 months ago
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/1aSrRsLkel https://t.co/gmh155ty6w
Laurent ARNAUD Lupusreference
2 years 10 months ago
✅ Probably one of my most important slides ⬇️
WHY IS MY #TREATMENT NOT WORKING (or not working enough) 😭 This is really a question we're dealing with everyday in #rheumatology when taking care of patients with #autoimmune and other rheumatic diseases 👍 https://t.co/osUPYSvuWf
Dr. John Cush RheumNow
2 years 10 months ago
Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.
https://t.co/8bAoqp79Mg https://t.co/K2Z1LwPTiS
Dr. John Cush RheumNow
2 years 10 months ago
NICE has approved upadacitinib (Rinvoq) for availability in England & Wales for use in adults w/ active ankylosing spondylitis not controlled with conventional therapy, only after TNF inhibitors are tried or not suitable https://t.co/MV47NPb2EF https://t.co/9Le2Sj5aNI
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.
Researchers examined two PsA and AS cohorts - patients with PsA with axial disease and isolated axial patients with AS with psoriasis.
Poster Hall